AbCellera Biologics Inc.
NASDAQ:ABCL
2.72 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Assets: | ||||||
| Current Assets: | ||||||
| Cash & Cash Equivalents
| 133.32 | 386.535 | 476.142 | 594.116 | 7.553 | 10.444 |
| Short Term Investments
| 627.265 | 499.95 | 246.835 | 0 | 0 | 0 |
| Cash and Short Term Investments
| 760.585 | 886.485 | 722.977 | 594.116 | 7.553 | 10.444 |
| Net Receivables
| 64.382 | 38.593 | 160.576 | 213.239 | 4.378 | 4.168 |
| Inventory
| 1.107 | 1.532 | 1.672 | 1.408 | 0.163 | 0 |
| Other Current Assets
| 20.911 | 75.413 | 21.247 | 5.97 | 1.811 | 0.55 |
| Total Current Assets
| 871.985 | 1,025.491 | 929.8 | 813.325 | 12.64 | 15.162 |
| Non-Current Assets: | ||||||
| Property, Plant & Equipment, Net
| 287.696 | 217.255 | 111.616 | 17.923 | 8.48 | 6.33 |
| Goodwill
| 47.806 | 47.806 | 47.806 | 31.5 | 0 | 0 |
| Intangible Assets
| 120.425 | 131.502 | 148.392 | 115.153 | 0 | 0 |
| Goodwill and Intangible Assets
| 168.231 | 179.308 | 196.198 | 146.653 | 0 | 0 |
| Long Term Investments
| 65.938 | 72.522 | 50.313 | 19.247 | 0 | 0 |
| Tax Assets
| 0 | 5.3 | 7.408 | 5.898 | 0 | 0 |
| Other Non-Current Assets
| 94.244 | 41.031 | 23.234 | 2.49 | 2.368 | 0 |
| Total Non-Current Assets
| 616.109 | 515.416 | 388.769 | 192.211 | 10.848 | 6.33 |
| Total Assets
| 1,488.094 | 1,540.907 | 1,318.569 | 1,005.536 | 23.488 | 21.492 |
| Liabilities & Equity: | ||||||
| Current Liabilities: | ||||||
| Account Payables
| 25.509 | 33.15 | 32.017 | 20.005 | 1.643 | 1.518 |
| Short Term Debt
| 6.158 | 5.583 | 3.652 | 0.19 | 2.886 | 2.531 |
| Tax Payables
| 0 | 0 | 35.683 | 36.152 | 0 | 0 |
| Deferred Revenue
| 26.07 | 21.612 | 7.536 | 6.589 | 3.236 | 2.334 |
| Other Current Liabilities
| 61.276 | 57.975 | 77.471 | 76.706 | 0.129 | 0.05 |
| Total Current Liabilities
| 119.013 | 118.32 | 120.676 | 103.49 | 7.895 | 6.433 |
| Non-Current Liabilities: | ||||||
| Long Term Debt
| 71.222 | 76.675 | 36.413 | 5.913 | 4.005 | 0.911 |
| Deferred Revenue Non-Current
| 104.11 | 60.317 | 60.758 | 25.894 | 1.336 | 2.261 |
| Deferred Tax Liabilities Non-Current
| 30.612 | 33.178 | 37.37 | 26.161 | 1.363 | 0 |
| Other Non-Current Liabilities
| 10.819 | 19.14 | 37.619 | 13.57 | -1.363 | 0.277 |
| Total Non-Current Liabilities
| 216.763 | 189.31 | 172.16 | 71.538 | 5.341 | 3.45 |
| Total Liabilities
| 335.776 | 307.63 | 292.836 | 175.028 | 13.236 | 9.883 |
| Equity: | ||||||
| Preferred Stock
| 0 | 0 | 0 | 0 | 7.546 | 7.557 |
| Common Stock
| 753.199 | 734.365 | 722.43 | 710.387 | 5.122 | 5.074 |
| Retained Earnings
| 279.787 | 426.185 | 267.666 | 114.202 | -4.716 | -2.505 |
| Accumulated Other Comprehensive Income/Loss
| -1.72 | -1.391 | 0.28 | 0 | 0 | -1.553 |
| Other Total Stockholders Equity
| 121.052 | 74.118 | 35.357 | 5.919 | 2.3 | 3.036 |
| Total Shareholders Equity
| 1,152.318 | 1,233.277 | 1,025.733 | 830.508 | 10.252 | 11.609 |
| Total Equity
| 1,152.318 | 1,233.277 | 1,025.733 | 830.508 | 10.252 | 11.609 |
| Total Liabilities & Shareholders Equity
| 1,488.094 | 1,540.907 | 1,318.569 | 1,005.536 | 23.488 | 21.492 |